SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: tonyt who wrote (19519)4/23/1998 7:50:00 PM
From: Hippieslayer  Respond to of 32384
 
a slam dunk for the submission, yes. not a slamdunk, but a lay-up for approval. Unless their is something that really concerns rhe panel, i don't see why a gel that works on a cancer that can't be topically treated shouldn't be approved. I'm sorta of hoping that Panretin gel has uses other than KS that will heavily exploited. The revenue base just for ks is too small.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News